January 21, 2021

RELIGARE | BROKING

Nifty Outlook

Extending yesterday's gains, the market continued its upward trend and gained nearly a percent. Supportive global cues led to a positive start which was further fuelled by the buying in index majors. Consequently, markets touched a new record high largely led by healthy buying in Auto and IT counters. On the benchmark front, the Nifty ended with gains of 0.9% at 14,645 levels. All the sectoral indices, except FMCG, ended in the green.

The recent buoyancy on the global front combined with the supportive local cues are helping the index to regain momentum. However, volatility is still high on the stock-specific front. Keeping all in mind, we feel it's prudent to continue with hedged positions and prefer index majors over the others.

	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	13950	15000	14000
News			

- **Hindustan Zinc's** Q3FY21 revenue was up 29.1% at Rs 6,033cr. Its net profit was up 35.8% to Rs 2,200cr as against Rs 1,620cr YoY.
- **Federal Bank** reported Q3FY21 numbers wherein net interest income was up 24.4% at Rs 1,437cr. Its net profit declined by 8.3% YoY to Rs 404.1cr.
- The power transmission & distribution business of Larsen & Toubro has won a slew of transmission line orders in Bangladesh. The scope of these packages involves design, supply, installation, testing and commissioning of extra high voltage transmission lines on turnkey basis.

Derivative	Ideas	Sectors to w	atch				
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET	Sector Name	Outlook
						IT	BULLISH
HAVELLS	BUY	CASH	1010-1015	970	1070	BANKS	BULLISH
						FMCG	BULLISH



Religare Sup	oer Idea**	•			
Scrip	Buy/Sell	СМР	Initiation Range	SL*	Target
SRTRANSFIN	BUY	1247.70	1230-1240	1180	1350

^{**}Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

^{*}Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

FII & DII	Cash Se	gment (Trade Stats				
Category	Amt.	MTD	FYTD		NO OF CONTRACTS	TURNOVER IN CR	
FII**	257	17809	166905	IDXFUTS	289801	27165	
	231	17005	100703	IDXOPT	33276957	10125	
DII**	-199	-12565	-122039	STKFUTS	786691	70297	
**Provisiona	al data as	on 19 th Ja	nuary, 2021				

January 21, 2021



Derivative Ideas

HAVELLS FUT added around 10% in open interest addition as LONG buildup was seen in it in till closing time. Current chart pattern also indicates further up move in its price. We suggest buying HAVELLS as per below levels.

Strategy:- BUY HAVELLS BETWEEN 1010-1015 SL 970 TARGET 1070.

Investment Pick - SBI Life Insurance Company Ltd.

Scrip	СМР	Recommendation Price	Target	Duration
SBI Life Insurance Company Ltd.	896.75	874	1,069	9-12 Months

- SBI Life Insurance Company Ltd. is a joint venture between State Bank of India and BNP Paribas Cardiff S.A. It is one of the leading life insurers in India with a healthy market share of 13.3% in terms of Individual rated premium. SBI Life offers a comprehensive range of life insurance and pension products at competitive prices, ensuring high standards of customer service and world-class operating efficiency.
- Within the industry, SBI Life is one of our preferred picks given its huge untapped client base, wide distribution reach and industry-leading cost ratios. Further, increased focus on business through digital channels and a strong distribution platform should lead to consistent market share gains for the company. We initiate with a Buy rating on the stock with a target price of Rs. 1069.

January 21, 2021



Mon Tue	Wed	Thu	Fri	Sat
Hindustan Media Ventures Ltd. Indiabulls Real Estate Ltd. Indiamart Intermesh Ltd Irb Infrastructure Developers Ltd. Mindtree Ltd. Majesco Ltd Rallis India Ltd. Trident Ltd. Trident Ltd. 19 Ceat Ltd. Csb Bank Ltd Dcm Shriram Limited Gateway Distriparks Ltd. Icic Lombard General Insurance Company Ltd Larsen & Toubro Infotech Ltd Bank Of Maharashtra Mold-Tek Packaging Limited Tata Communications Ltd. Tv18 Broadcast Ltd.	 Bajaj Finserv Ltd. Bajaj Finance Limited Everest Industries Ltd. Federal Bank Ltd. Gmm Pfaudler Ltd. Havells India Ltd. Hdfc Asset Management Company Ltd Hindustan Zinc Ltd. L&T Technology Services Ltd 	 Asian Paints Ltd. Bajaj Auto Ltd. Bajaj Holdings & Investment Ltd. Bandhan Bank Ltd Biocon Ltd. Cyient Limited 	• Century Textiles & Industries Ltd. • Crompton Greaves Consumer Electricals Ltd • Gland Pharma Ltd • Hdfc Life Insurance Company Ltd • Indian Bank • Jsw Steel Ltd. • Reliance Capital Ltd. • Reliance Home Finance Ltd • Sbi Life Insurance Company Ltd	Birla Corporation Ltd. Dcb Bank Limited Jm Financial Ltd. Mahindra Lifespace Developers Ltd. Ultratech Cement Ltd.

For complete so	chedule of more	Company Results Ca	lendar <u>cli</u>	ck here.						
CACT Calenda	ar - January 20)21 (E.G.M.)								
Sun	Mon	Tue	Wed	Thu			Fri		Sa	it
17	18	19	20	21	22 • T	irupati Starch & Ch	emicals Ltd.		23	
CACT Calendar - January 2021 (Buy Back of Shares)										
Sun		Mon		Tue	Wed		Thu	Fri		Sat
17	Archidply Inc.	dustries Ltd.		19	20	21		22	23	
CACT Calen	dar - January	2021 (Cash Divi	dend)							
Sun	Mon	Tue		Wed		Thu		Fri		Sat
17	18	19	20		21		22			23
		IRB Invit Fund				chnologies Ltd. terprises Ltd.	• Tov	SC Ltd. ver Infrastructure Trus oro Ltd.	t	

January 21, 2021



Re	lig	jar	e	יחו	ve:	stı	me	nt	Cal	ls
----	-----	-----	---	-----	-----	-----	----	----	-----	----

Religate investment calls								
Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
Cummins India	31-Jan-2020	Buy	Investment Call	585	705	20.5%	618	14.0%
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	546	13.2%
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	323	16.6%
Godrej Consumer Products	16-Sept-2020	Hold	Investment Call	706	845	19.7%	801	5.5%
Britannia Industries	22-Oct-2020	Buy	High Conviction Ideas	3,397	4,265	25.5%	3,592	18.7%
Castrol India	02-Nov-2020	Buy	Investment Call	114	151	32.5%	128	17.6%
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas/ Diwali Picks	450	709	57.6%	596	18.9%
Nippon Life India Asset Management	09-Nov-2020	Hold	Diwali Picks	285	348	22.1%	335	3.9%
Sudarshan Chemical Industries	09-Nov-2020	Buy	Diwali Picks	442	583	31.9%	505	15.4%

*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

Hold - Potential Returns <10% over 12 months

For Religare Investment calls performance <u>click here</u>

January 21, 2021



Rel	ligare I	nvestmen	t Calls
-----	----------	----------	---------

Religate investment calls								
Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
ітс	19-Nov-2020	Hold	Investment Call	190	238	25.3%	218	9.3%
Dabur India	24-Nov-2020	Buy	High Conviction Ideas	509	616	21.0%	538	14.6%
Axis Bank	28-Dec-2020	Hold	New Year Picks 2021	610	721	18.2%	676	6.7%
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	847	15.5%
IRCTC	28-Dec-2020	Buy	New Year Picks 2021	1,409	1,755	24.6%	1,453	20.8%
JK Lakshmi Cement	28-Dec-2020	Buy	New Year Picks 2021	337	428	27.0%	328	30.3%
Mahindra and Mahindra	28-Dec-2020	Hold	New Year Picks 2021	711	889	25.0%	825	7.8%
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	168	21.7%
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	906	25.3%
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	897	19.2%

*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

For Religare Investment calls performance click here **Hold** - Potential Returns <10% over 12 months



Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

For cash market trading						For 1L margin*		
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated		Total	Per Call	
Intraday Calls	Intraday	2 - 3	< 1 day	25%		25,000	8,000	
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%		30,000	4,000	
Master Pick	Weekly	1	1 month	15%		15,000	5,000	
Religare Alpha	Opportunity	NA	2 - 3 months	20%		20,000	As per weightage	
Cash		NA		10%		10,000		
Intraday Calls	These calls are flashed live on Ms Lync and ODIN with the purpose of squaring off positions on the same day. As a policy, we restrict our intraday cash market calls to less than 4 calls a day. Hence, funds should be allocated accordingly to have provision to trade in all calls.							
Live / RMD Calls	2 super ideas are flashed in RMD daily with a view of 3-4 days. Additionally as per market opportunity, we flash live calls during the day (including BTST calls). 3-4 such calls are made on a daily basis which might be open for 3-4 days. Funds should be allocated keeping in mind that there will be 7-8 such open calls daily.							
Master Pick	This is our weekly recommendation shortlisted on the basis of techno-funda analysis. 15% of funds is recommended to be allocated for Master Pick considering that there will be 3 open calls. The average open duration for this call will be 1 month.							
Religare Alpha	This is a portfolio of 8-10 stocks which are held with a view of 2-3 months. It is recommended to allocate 20% of funds for building this portfolio which will provide stability to the overall trading portfolio.							
Cash	10% surplus cash in the portfolio should be kept for the purposes of allocating it to opportunities as and when they arrive.							

For derivative market trading					For 1L margin*			
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call		
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000		
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000		
Cash		NA		10%	10,000			
Derivative Ideas	1 derivative idea is shared in RMD daily. It can be a plain vanilla F&O buy/sell call or an option strategy. Funds should be allocated assuming 2 such calls will be open at any time. These calls are open for 3-4 days on an average.							
Live Calls	These calls are flashed on MS Lync and ODIN during live market hours. These calls can be intraday or with a view of 2-3 days. Funds should be allocated considering 2 such calls will be open at any time. 3/4 times, these calls will be on Nifty / Bank Nifty only.							
Cash	It is recommended to hold 10% cash to capitalize on any opportunity that may arise in markets.							

January 21, 2021



Research Analysts

Ajit Mishra ajit.mishra@religare.com

Himanshu Sharma himanshu.sharma1@religare.com

Manoj M Vayalar manoj.vayalar@religare.com

Nirvi Ashar nirvi.ashar@religare.com

Rohit Khatri rohit.khatri@religare.com

Suhanee Shome suhanee.shome@religare.com

January 21, 2021



Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below, are given separately]

S. No.	Statement			
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
		1	1	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
•		•	•	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest (if answer to F (a) above is Yes:

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below]

SSNo	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results